HER2 Alterations in Non-Small Cell Lung Cancer - Episode 1

Biomarker Testing in NSCLC: Clinical Scenario

September 12, 2022

Solange Peters, MD, PhD, Timothy Craig Allen, MD, JD, FCAP, Ticiana A. Leal, MD, Mark A. Socinski, MD, Anil Vachani, MD, MS

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: Biomarker Testing in NSCLC: Clinical Scenario

EP. 2: Approaches to Biomarker Testing in NSCLC

EP. 3: Liquid vs Solid Tumor Biopsies in NSCLC

EP. 4: HER2 Alterations in NSCLC: Clinical Scenario

EP. 5: The Role of HER2 Alterations in NSCLC

EP. 6: Testing Patients with NSCLC for HER2 Mutations

EP. 7: Current Treatment Options in NSCLC

EP. 8: Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

EP. 9: HER2-Targeted Therapies in NSCLC

EP. 10: Major Adverse Events of Anti-HER2 Therapies

EP. 11: Unmet Needs in NSCLC Therapy

EP. 12: Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

EP. 13: Novel HER2-Targeted Therapies for NSCLC